

# Allergan Inc

AGN

## Restasis Kicker Drives Strong 2Q Upside Surprise

- Better-Than-Expected 2Q Results:** Allergan reported better-than-expected second quarter earnings of \$0.78 per share (\$0.05 above our estimate) on higher product sales of \$591 M (\$37.4 M above CSFB estimate). Core eye care sales tracked better-than-expected at \$325 million (\$19 M above CSFB estimate), largely based on exceptional Restasis (dry eye) sales of \$46.3 M (up 130% and \$14.3 M above CSFB estimate). Restasis realized sales tracked well above IMS 60% volume growth indicators, supported by new DTC advertising campaign momentum. Botox also registered strong sales of \$212.5 M, up 20% vs. only 17% in 1Q and beating CSFB targets by \$7.3 M. Botox has also benefited from re-invigorated DTC campaign initiatives.
- Core Portfolio Strength:** New promotional campaigns are effectively driving better-than-expected gains across Allergan's core pharmaceutical portfolio. Botox has re-established strength in core therapeutic markets, and appears to have strengthened its position in European cosmetic markets. Restasis has also emerged as a solid incremental earnings driver, with management elevating 2005 sales forecasts to a range of \$165-\$185 million.
- Earnings Revision and Target Price Adjustment:** We are raising our 2005 earnings forecast by \$0.04 to a new level of \$3.22 to reflect second quarter upside. We are also adjusting upward our earnings forecasts by \$0.08 to \$3.73 in 06 and by \$0.11 to \$4.30 in 07 due to an elevated 05 base. Upward earnings revisions also support an upward revision in our target price from a prior level of \$88 to a new level of \$95.
- While Allergan has re-invigorated growth behind key eye care products, our Neutral stance reflects on-going concerns over Botox growth reliance. We estimate Botox represents over 50% of Allergan's core earnings base.**

Allergan is a leading research-based specialty pharmaceutical company and is among the global leaders in ophthalmology (prescription drugs, OTC solutions, intraocular lenses).


### research team

<b>Ken Kulju</b> Research Analyst 212 538 8391 kenneth.kulju@csfb.com	<b>Jessica Li, Ph.D</b> Research Analyst 212 538 2586 jessica.li.2@csfb.com	<b>Tania Dimitrova</b> Research Analyst 212 325 3297 tania.dimitrova@csfb.com
--	--	--

**IMPORTANT DISCLOSURES AND ANALYST CERTIFICATIONS ARE IN THE DISCLOSURE APPENDIX.** U.S. Disclosure: CSFB does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Customers of CSFB in the United States can receive independent, third party research on the company or companies covered in this report, at no cost to them, where such research is available. Customers can access this independent research at [www.csfb.com/ir](http://www.csfb.com/ir) or call 1 877 291 2683 or email [equity.research@csfb.com](mailto:equity.research@csfb.com) to request a copy of this research.

Rating	<b>NEUTRAL*</b>
Price (26 Jul 05)	85.42 (US\$)
Target price (12 months)	95.00 (US\$)
52 week high - low	86.99 - 67.67
Market cap. (US\$m)	11,468.06
Enterprise value (US\$m)	11,468.06
Region / Country	Americas / United States
Sector	Specialty Pharmaceuticals
Analyst's Coverage Universe	Specialty Pharmaceuticals
Weighting (vs. broad market)	OVERWEIGHT
Date	27 July 2005

\* Stock ratings are relative to the coverage universe in each analyst's or each team's respective sector.



On 07/26/05 the S&P 500 index closed at 1,236.79

Year	12/04A	12/05E	12/06E
EPS (CSFB adj., US\$)	2.77	3.22	3.73
Prev. EPS (US\$)		3.18	3.65
P/E (x)	30.8	26.5	22.9
P/E rel. (%)	168.4	161.7	151.7
Q1 EPS	0.60	0.76	0.85
Q2	0.64	0.78	0.92
Q3	0.67	0.78	0.96
Q4	0.86	0.89	1.00

Number of shares (m)	134.26	IC (12/05E, US\$m)	1,819.53
BV/Share (Current, US\$)	—	EV/IC (x)	6.3
Net Debt (Current, US\$m)	-167.0	Dividend (12/04A, US\$m)	0.39
Net debt/Total cap. (Current)	5.0%	Dividend yield	0.5%

Year	12/04A	12/05E	12/06E
Revenues (US\$m)	2,045.7	2,268.2	2,399.3
EBITDA (US\$m)	549.5	610.5	681.9
OCFPS (US\$)	—	—	—
P/OCF (x)	—	—	—
EV/EBITDA (x)	20.9	18.8	16.8
ROIC	—	13.2%	13.2%

Source: Company data, CREDIT SUISSE FIRST BOSTON (CSFB) estimates

## Investment Summary

Allergan reported better-than-expected second quarter earnings of \$0.78 per share (\$0.05 above our estimate) on higher product sales of \$591 M (\$37.4 M above CSFB estimate). Core eye care sales tracked better-than-expected at \$325 million (\$19 M above CSFB estimate), largely based on exceptional Restasis (dry eye) sales of \$46.3 M (up 130% and \$14.3 M above CSFB estimate). Restasis realized sales tracked well above IMS 60% volume growth indicators, supported by new DTC advertising campaign momentum. Botox also registered strong sales of \$212.5 M, up 20% vs. only 17% in 1Q and beating CSFB targets by \$7.3 M. Botox has also benefited from re-invigorated DTC campaign initiatives.

**Exhibit 1: Allergan Variance Table**

Allergan	CSFB 2Q05E	Reported 2Q05A	Variance
<b>Total Product Sales</b>	\$ 553.7	\$ 591.0	\$ 37.4
<b>Eye Care</b>	\$ 306.0	\$ 325.0	\$ 19.0
Alphagan (total)	\$ 65.0	\$ 64.3	\$ (0.7)
Lumigan Line	\$ 64.0	\$ 61.5	\$ (2.5)
Restasis	\$ 32.0	\$ 46.3	\$ 14.3
<b>Botox</b>	\$ 205.2	\$ 212.5	\$ 7.3
<b>Skin Care</b>	\$ 30.4	\$ 30.4	\$ -
Cost of Revenues	\$ 94.1	\$ 94.1	\$ -
Gross Profit	\$ 452.3	\$ 479.3	\$ 27.0
Gross Margin	81.7%	81.1%	- 60 bps
SG&A	\$ 218.7	\$ 240.7	\$ 22.0
R&D	\$ 98.0	\$ 90.8	\$ (7.2)
<b>Operating Income</b>	\$ 135.6	\$ 147.8	\$ 12.2
<b>Operating Margin</b>	25.0%	26.0%	+ 98 bps
Other Income	\$ 1.9	\$ 0.8	\$ (1.1)
Taxes	\$ 39.9	\$ 44.6	\$ 4.7
Rate	29.0%	30.0%	+101 bps
Net Income	\$ 97.4	\$ 103.7	\$ 6.3
<b>EPS</b>	\$ 0.73	\$ 0.78	\$ 0.05
Shares	132.6	132.2	

Source: Company data, CSFB estimates

### Allergan Core Franchise Performance


#### Restasis: Surprisingly Strong Sales in the Quarter

Restasis remains in a strong growth mode. IMS prescription trends continue to point to robust on-going uptake for Restasis in severe dry eye therapy. Allergan has been leveraging this momentum with the start of new DTC advertising in both print and TV channels.

Although Restasis total prescription trend in the quarter pointed to a 60% year-over-year growth rate, Allergan reported surprisingly strong sales of \$46.3 million, a 130% increase from the same period last year. Allergan raised price for Restasis by 3.5% in February this year.


To reflect higher-than-expected Restasis sales in the second quarter, we are moving up our Restasis sales forecast from \$156 million to \$172 million for 2005, and from \$192 million to \$211 million in 2006.

**Exhibit 2:**



Source: Company data, CSFB estimates

**Exhibit 3:**




Source: Company data, CSFB estimates

**Lumigan**

Allergan reported slightly lower sales generated from Lumigan at \$61.5 million in the quarter. As shown in the relative growth chart below, the four-week moving average new prescription growth trends suggest Lumigan generating growth of about 10%-12% in volume terms.

**Exhibit 4:**




Source: Company data, CSFB estimates

**Alphagan/Alphagan P**

Allergan's Alphagan franchise has been losing ground largely to Pfizer's Xalatan. Chart 3 shows year-over-year new prescription growth rates of Alphagan/Alphagan P slid to the negative territory since May. Management expressed confidence that the FDA will approve a new Alphagan product formulation, Alphagan-Z, shortly. This product conversion strategy is largely expected to sustain core Alphagan franchise sales in the face of generic challenges from Alcon's Falcon generics operation.




Exhibit 5:



Source: Company data, CSFB estimates

Exhibit 6: Xalatan Gaining Shares At the Expense of Alphagan Franchise



Source: Company data, CSFB estimates


## Botox

Botox remains a critical driver for Allergan, positioning to remain in a healthy growth mode in global cosmetic markets, considering its still early stage of introduction in Europe. This neurotoxin also possesses considerable opportunities in new therapeutic applications in new areas, such as hyperhidrosis and migraine headache therapy.


Allergan reported strong sales in Botox of \$212.5 million, up 20% vs. only 17% in 1Q (\$7.3 M above CSFB estimate), reflecting the re-introduction of the DTC campaign and the dissipation of the adverse publicity from an incident involving use of bogus Botox in Florida.

Allergan began a new national DTC campaign for Botox Cosmetic and regional ad campaign for Cosmetic Therapeutic (hyperhidrosis and cervical dystonia) in late March. To reflect the effective new Botox DTC campaign, we are raising our 05 sales forecast from \$818 million to \$832 million.

Exhibit 7:



Source: Company data, CSFB estimates

**Exhibit 8:**

Source: Company data, CSFB estimates

### Earnings Revision and Target Price Adjustment

We are raising our 2005 earnings forecast by \$0.04 to a new level of \$3.22 to reflect second quarter's \$0.05 earnings upside. We are also adjusting upward our earnings forecasts by \$0.08 to \$3.73 in 06 and by \$0.11 to \$4.30 in 07 due to an elevated 05 base.

The elevation in Allergan's earnings foundation prompted us to raise our target price for the stock from a prior level of \$88 to a higher level of \$95.

### Conclusion

New promotional campaigns are effectively driving better-than-expected gains across Allergan's core pharmaceutical portfolio. Botox has re-established strength in core therapeutic markets, and appears to have strengthened its position in European cosmetic markets. Restasis has also emerged as a solid incremental earnings driver, with management elevating 2005 sales forecasts to a range of \$165-\$185 million.

We are raising our 2005 earnings forecast by \$0.04 to a new level of \$3.22 to reflect second quarter upside. We are also adjusting upward our earnings forecasts by \$0.08 to \$3.73 in 06 and by \$0.11 to \$4.30 in 07 due to an elevated 05 base. Upward earnings revisions also support an upward revision in our target price from a prior level of \$88 to a new level of \$95.

While Allergan has re-invigorated growth behind key eye care products, our Neutral stance reflects on-going concerns over Botox growth reliance. We believe Botox represents over 50% of Allergan's core earnings base.

**Exhibit 9: CSFB Value Equation Analysis**

	<b>Market Expectations</b>	<b>CSFB Expectations</b>
<b>Income Statement Data:</b>		
<b>Fiscal Year (Income statement date):</b>	<b>2006</b>	<b>2006</b>
Sales (Income statement date):	2,399.3	2,399.3
<b>EBITA</b>	<b>681.9</b>	<b>681.9</b>
EBITA margin (%):	28.4%	28.4%
Tax rate:	28.5	28.5
Analyst EPS Estimate	\$3.71	\$3.70
<b>Business Model Value Creation:</b>		
<b>EBITA (3-5 year) growth rate:</b>	<b>14.4</b>	<b>13.8</b>
<b>Pretax Capital Efficiency (ROIIC)</b>	<b>85.0</b>	<b>85.0</b>
Note: Aftertax ROIIC (%)	61%	61%
<b>Investment Neighborhood:</b>		
Required Rate of Return (cost of capital):	11.50	11.50
C.A.P. (Duration of value creation):	Dec-2021	Dec-2021
<b>CSFB Value-Equation Share Price Est.:</b>		
Price Date:	27-Jul-05	27-Jul-06
<b>Actual Price</b>	<b>\$89.20</b>	<b>\$95.06</b>
Diff (%)	0%	7%

Source: Company data, CSFB estimates

Exhibit 10: Allergan Sales Analysis

	2005													
	2004			2005			2005			2005				
	FY 2002	FY 2003	Mar-04 1QA	Jun-04 2QA	Sep-04 3QA	Dec-04 4QA	FY 2004	Mar-05 1QA	Jun-05 2QA	Sep-05 3QE	Dec-05 4QE	FY 2005	FY 2006	FY 2007
<b>Eye Care Pharmaceuticals</b>														
Alphagan	108.6	11.0	1.0	0.0	0.0	0.0	1.0	1.0	0.6	0.0	0.0	1.6	1.0	1.0
Alphagan-P/Z	140.0	275.8	68.3	62.4	73.0	65.2	288.9	64.7	62.0	60.0	50.0	236.7	170.2	144.7
Combigan	-	-	-	-	-	-	-	1.0	1.7	5.0	5.0	12.7	33.0	60.0
Alphagan (Total)	248.6	286.8	69.3	62.4	73.0	65.2	289.9	66.7	64.3	65.0	55.0	251.0	204.2	205.7
Lumigan	123.1	181.4	53.5	57.3	60.3	61.8	232.9	62.0	61.5	66.0	68.0	257.5	301.3	331.4
Lumigan/Timolol	123.1	181.4	53.5	57.3	60.3	61.8	232.9	62.0	61.5	66.0	68.0	257.5	309.1	355.4
Lumigan (Total)	371.7	468.2	127.7	125.0	137.9	131.3	521.9	133.3	130.2	136.0	128.0	528.5	533.3	581.1
<b>Total Glaucoma</b>	74.8	83.0	22.5	26.0	31.2	32.0	111.7	24.8	28.6	34.3	35.2	122.9	135.2	148.7
Acular/Acular PF (NSAID)														
<b>Anti-Infective</b>														
Ocuflox (anti-infective)	97.0	70.0	10.0	6.0	1.0	3.0	20.0	2.0	2.0	1.0	1.0	6.0	4.8	3.8
Zymar (Gatifloxacin)	-	35.0	15.0	19.0	19.0	23.0	76.0	24.8	25.0	24.0	25.3	99.1	109.0	114.5
<b>Total anti-infective line</b>	97.0	105.0	25.0	25.0	20.0	26.0	96.0	26.8	27.0	25.0	26.3	105.1	113.8	118.3
Betagan	14.0	11.5	2.0	3.0	3.0	3.0	11.0	2.0	3.0	3.0	3.0	11.0	11.0	11.0
Pred Forte	19.3	19.3	3.0	4.7	4.8	3.4	16.0	2.9	4.7	4.7	3.4	15.7	15.7	15.7
<b>Dry Eye</b>														
Restasis	-	38.4	21.3	20.1	24.1	34.3	99.8	37.3	46.3	45.0	43.0	171.6	211.1	236.4
INS365	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total Rx Dry Eye</b>	-	38.4	21.3	20.1	24.1	34.3	99.8	37.3	46.3	45.0	43.0	171.6	211.1	236.4
<b>Anti-histamine</b>														
Alcicril	32.7	32.2	8.0	8.0	6.0	8.0	30.0	8.6	10.0	8.0	8.6	32.4	38.1	41.2
Elestat/Relestat (Epinastine)	-	5.0	5.6	8.0	6.0	10.0	29.6	7.3	10.4	9.0	13.0	39.7	51.6	67.1
<b>Total Anti-histamine</b>	32.7	37.2	13.6	16.0	12.0	18.0	59.6	15.9	20.4	17.0	21.6	72.1	89.7	108.2
Posurdex	-	-	-	-	-	-	-	-	-	-	-	-	-	35.0
Menantine	-	-	-	-	-	-	-	-	-	-	-	-	-	5.0
Artificial tears	163.0	173.0	45.0	43.0	40.0	42.0	170.0	43.0	50.0	50.0	42.0	185.0	165.0	155.0
Other	54.7	57.6	12.0	14.8	12.4	12.0	51.2	12.0	14.8	15.0	12.0	53.8	53.8	52.2
<b>Total Eye Care Pharma</b>	827.2	999.5	272.1	277.6	285.4	302.0	1,137.2	298.0	325.0	330.1	314.5	1,245.7	1,308.6	1,446.6
<b>Botox</b>	439.7	563.9	150.7	176.9	174.6	202.9	705.1	176.3	212.5	209.5	233.3	831.7	938.0	1,069.5
<b>Total Botox Franchise Growth</b>	42%	28%	22%	24%	25%	29%	25%	17%	20%	20%	15%	18%	13%	14%
<b>Skin Care</b>														
Tazorac cream/gel	62.1	65.9	16.7	16.0	17.5	19.5	69.7	21.0	20.5	22.0	21.5	85.0	89.2	93.7
Avage	-	14.3	1.3	1.2	1.3	1.6	5.4	1.6	1.5	1.5	2.0	6.6	8.0	10.0
Prevage	-	-	-	-	-	-	-	0.5	0.5	0.5	0.7	2.2	3.0	4.0
Tazorac oral	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other	28.1	29.1	6.7	7.9	6.0	8.4	29.0	6.7	7.9	6.0	8.4	29.0	29.0	29.0
<b>Total Skin Care</b>	90.2	109.3	24.7	24.4	24.8	29.5	104.1	29.8	30.4	30.0	32.6	122.8	129.2	136.7
<b>Year-over-year Growth</b>	14%	21%	-5%	-1%	-15%	0%	-5%	21%	25%	21%	10%	18%	5%	6%
<b>Total Pharmaceuticals</b>	1,357.1	1,672.7	447.5	478.9	484.8	534.4	1,946.4	504.1	567.9	569.6	580.4	2,200.1	2,375.7	2,652.8
<b>Year-over-year Growth</b>	19%	23%	21%	14%	15%	16%	16%	13%	19%	17%	9%	13%	8%	12%

Source: Company data, CSFB estimates



**Exhibit 11: Allergan Income Statement Analysis**

	2004				2005									
	Mar-04	Jun-04	Sep-04	Dec-04	Mar-05	Jun-05	Sep-05	Dec-05						
	1QA	2QA	3QA	4QA	1QA	2QA	3QE	4QE						
Total Product Sales	1,357.1	1,672.7	447.5	478.9	484.8	534.4	1,945.7	504.1	567.9	569.6	580.4	2,222.0	2,399.3	2,679.2
Contract Sales	63.6	82.7	24.9	27.3	26.0	21.8	100.0	23.1	23.1	0.0	0.0	46.2	0.0	0.0
<b>Total Sales</b>	<b>1,420.7</b>	<b>1,755.4</b>	<b>472.4</b>	<b>506.2</b>	<b>510.8</b>	<b>556.2</b>	<b>2,045.7</b>	<b>591.0</b>	<b>591.0</b>	<b>569.6</b>	<b>580.4</b>	<b>2,268.2</b>	<b>2,399.3</b>	<b>2,679.2</b>
Cost of Revenues	253.6	320.3	87.6	96.2	99.1	103.8	386.7	94.1	111.7	108.2	107.4	421.4	427.5	455.5
Gross Profit	1,167.1	1,435.1	384.8	410.0	411.7	452.4	1,659.0	433.1	479.3	461.4	473.0	1,846.8	1,971.8	2,223.7
Total Gross Profit	1,170.8	1,436.6	384.8	410.0	411.7	452.4	1,659.0	433.1	479.3	461.4	473.0	1,846.8	1,971.8	2,223.7
SG&A	596.7	693.6	180.6	196.7	195.5	206.1	778.9	210.1	240.7	210.7	202.0	863.5	896.6	996.6
Research & Development	230.9	305.5	86.1	88.5	83.0	88.0	345.6	81.9	90.8	106.5	108.5	387.7	408.2	455.5
Operating income/EBIT	343.2	437.5	118.1	124.8	133.2	158.3	534.5	141.1	147.8	144.1	162.5	595.5	666.9	771.7
Interest Expense	-19.4	-15.6	-3.7	-3.7	-6.8	-3.9	-18.1	-4.5	-4.6	-3.1	-3.1	-15.3	-12.5	-12.5
Interest Income	18.7	13.0	2.0	2.2	2.6	7.3	14.1	5.4	6.1	4.3	4.7	20.5	20.4	24.5
Other	0.7	-5.6	-2.5	-1.2	-1.4	0.3	-4.8	1.0	-0.7	1.0	2.3	12.0	12.0	4.0
Total other income (expense)	0.0	-8.2	-4.2	-2.7	-5.6	3.7	-8.8	1.9	0.8	2.2	2.6	7.5	19.9	16.1
Pretax income	343.2	429.3	113.9	122.1	127.6	162.0	525.7	143.0	148.6	146.3	165.1	603.0	686.9	787.8
Provision for income taxes	96.3	123.4	34.2	36.4	38.4	46.8	155.8	41.7	44.6	42.4	46.6	175.3	195.8	224.5
Minority Interest	0.7	0.8	0.3	0.4	0.2	0.3	1.2	0.3	0.3	0.3	0.3	1.2	1.2	1.2
Net Income	246.2	305.1	79.4	85.3	89.0	114.9	368.7	101.0	103.7	103.6	118.2	426.5	489.9	562.1
Average shares	131.5	132.5	133.0	133.7	132.2	133.0	133.0	132.6	132.2	132.2	132.2	132.2	131.4	130.6
<b>Earnings per share</b>	<b>1.87</b>	<b>2.30</b>	<b>0.60</b>	<b>0.64</b>	<b>0.67</b>	<b>0.86</b>	<b>2.77</b>	<b>0.76</b>	<b>0.78</b>	<b>0.78</b>	<b>0.89</b>	<b>3.22</b>	<b>3.73</b>	<b>4.30</b>

**Margin Analysis**

Gross margin	82.2%	81.8%	81.5%	81.0%	80.6%	81.3%	81.1%	81.0%	81.5%	81.4%	83.0%
Gross Margin (Pharma)			85.4%	85.0%	84.4%	84.2%	84.0%	81.0%	81.5%	83.1%	82.2%
Gross Margin (Contract)			10.0%	10.0%	10.0%	10.0%	10.0%	10.0%	34.8%	38.1%	37.4%
SG&A % sales	42.0%	39.5%	38.2%	38.9%	38.3%	37.1%	38.1%	37.0%	34.8%	38.9%	37.4%
SG&A % pharma sales	44.0%	41.5%	40.4%	41.1%	40.3%	38.6%	40.0%	42.4%	34.8%	38.9%	37.4%
R&D % sales	16.3%	17.4%	18.2%	17.5%	16.2%	15.8%	16.9%	15.4%	18.7%	17.1%	17.0%
R&D % pharma sales	17.0%	18.3%	19.2%	18.5%	17.1%	16.5%	17.8%	16.0%	18.7%	17.5%	17.0%
Operating margin	24.2%	24.9%	26.4%	26.1%	27.5%	29.6%	26.1%	26.0%	28.0%	26.3%	27.8%
Pre-tax margin	24.2%	24.5%	25.5%	25.5%	26.3%	30.3%	25.7%	26.2%	25.7%	26.6%	28.6%
Tax rate	28.1%	28.7%	30.0%	29.8%	30.1%	28.9%	29.6%	30.0%	29.0%	29.1%	28.5%
Net margin	17.3%	17.4%	17.7%	17.8%	18.4%	21.5%	18.0%	18.3%	18.2%	18.8%	20.4%
<b>Year/Year Changes</b>											
Sales	19%	23%	21%	14%	15%	16%	16.3%	18.6%	17.5%	14.2%	8.0%
Gross profit	23%	23%	19%	13%	14%	16%	15.5%	16.9%	12.1%	11.3%	6.8%
SG&A	19%	16%	6%	7%	15%	22%	12.3%	22.4%	7.8%	-2.0%	3.8%
R&D	23%	32%	54%	15%	2%	-4%	13.1%	2.6%	28.3%	12.2%	5.3%
Net income	25%	24%	12%	22%	17%	30%	20.8%	21.6%	16.3%	15.7%	14.9%
Earnings per share	27%	23%	11%	21%	18%	29%	20.4%	23.0%	16.3%	16.3%	15.6%

Source: Company data, CSFB estimates


**Companies Mentioned** (Price as of 27 Jul 05)

Allergan Inc (AGN, \$85.42, NEUTRAL, TP \$88.00, OVERWEIGHT)

**Disclosure Appendix****Important Global Disclosures**

I, Ken Kulju, certify that (1) the views expressed in this report accurately reflect my personal views about all of the subject companies and securities and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

See the *Companies Mentioned* section for full company names.

**3-Year Price, Target Price and Rating Change History Chart for AGN**

AGN Date	Closing Price (US\$)	Target Price (US\$)	Rating	Initiation/Assumption
9/6/02	57.09	64	OUTPERFORM	
2/27/03	63.89		NOT RATED	
7/7/03	81.21	83	NEUTRAL	X
4/22/04	90.64	85		
5/3/04	89.1	91		
7/12/04	81.91	85		
2/8/05	74.12	82		
6/10/05	81.75	85		
7/14/05	86.2	88		

The analyst(s) responsible for preparing this research report received compensation that is based upon various factors including CSFB's total revenues, a portion of which are generated by CSFB's investment banking activities.

**Analysts' stock ratings are defined as follows\*\*\*:**

**Outperform:** The stock's total return is expected to exceed the industry average\* by at least 10-15% (or more, depending on perceived risk) over the next 12 months.

**Neutral:** The stock's total return is expected to be in line with the industry average\* (range of  $\pm 10\%$ ) over the next 12 months.

**Underperform\*\*:** The stock's total return is expected to underperform the industry average\* by 10-15% or more over the next 12 months.

\*The industry average refers to the average total return of the analyst's industry coverage universe (except with respect to Asia/Pacific, Latin America and Emerging Markets, where stock ratings are relative to the relevant country index, and CSFB HOLT Small and Mid-Cap Advisor stocks, where stock ratings are relative to the regional CSFB HOLT Small and Mid-Cap Advisor investment universe.

*\*\*In an effort to achieve a more balanced distribution of stock ratings, the Firm has requested that analysts maintain at least 15% of their rated coverage universe as Underperform. This guideline is subject to change depending on several factors, including general market conditions.*

*\*\*\*For Australian and New Zealand stocks a 7.5% threshold replaces the 10% level in all three rating definitions.*

**Restricted:** In certain circumstances, CSFB policy and/or applicable law and regulations preclude certain types of communications, including an investment recommendation, during the course of CSFB's engagement in an investment banking transaction and in certain other circumstances.

**Volatility Indicator [V]:** A stock is defined as volatile if the stock price has moved up or down by 20% or more in a month in at least 8 of the past 24 months or the analyst expects significant volatility going forward. All CSFB HOLT Small and Mid-Cap Advisor stocks are automatically rated volatile. All IPO stocks are automatically rated volatile within the first 12 months of trading.

**Analysts' coverage universe weightings\* are distinct from analysts' stock ratings and are based on the expected performance of an analyst's coverage universe\*\* versus the relevant broad market benchmark\*\*\*:**

**Overweight:** Industry expected to outperform the relevant broad market benchmark over the next 12 months.

**Market Weight:** Industry expected to perform in-line with the relevant broad market benchmark over the next 12 months.

**Underweight:** Industry expected to underperform the relevant broad market benchmark over the next 12 months.

*\*CSFB HOLT Small and Mid-Cap Advisor stocks do not have coverage universe weightings.*

*\*\*An analyst's coverage universe consists of all companies covered by the analyst within the relevant sector.*

*\*\*\*The broad market benchmark is based on the expected return of the local market index (e.g., the S&P 500 in the U.S.) over the next 12 months.*

**CSFB's distribution of stock ratings (and banking clients) is:**

Global Ratings Distribution		
<b>Outperform/Buy*</b>	39%	(54% banking clients)
<b>Neutral/Hold*</b>	43%	(54% banking clients)
<b>Underperform/Sell*</b>	15%	(47% banking clients)
<b>Restricted</b>	3%	

*\*For purposes of the NYSE and NASD ratings distribution disclosure requirements, our stock ratings of Outperform, Neutral, and Underperform most closely correspond to Buy, Hold, and Sell, respectively; however, the meanings are not the same, as our stock ratings are determined on a relative basis. (Please refer to definitions above.) An investor's decision to buy or sell a security should be based on investment objectives, current holdings, and other individual factors.*

CSFB's policy is to update research reports as it deems appropriate, based on developments with the subject company, the sector or the market that may have a material impact on the research views or opinions stated herein.

CSFB's policy is only to publish investment research that is impartial, independent, clear, fair and not misleading. For more detail please refer to CSFB's Policies for Managing Conflicts of Interest in connection with Investment Research: [http://www.csfb.com/research-and-analytics/disclaimer/managing\\_conflicts\\_disclaimer.html](http://www.csfb.com/research-and-analytics/disclaimer/managing_conflicts_disclaimer.html)

*See the Companies Mentioned section for full company names.*

**Price Target:** (12 months) for (AGN)

**Method:** CSFB Value Equation

**Risks:** Risks to our target price include operational, regulatory, and pipeline risks associated with the company which would cause a slow down in growth; any slow down in growth or growth prospects.

*See the Companies Mentioned section for full company names.*

The subject company (AGN) currently is, or was during the 12-month period preceding the date of distribution of this report, a client of CSFB.

CSFB provided investment banking services to the subject company (AGN) within the past 12 months.

CSFB has received investment banking related compensation from the subject company (AGN) within the past 12 months.

CSFB expects to receive or intends to seek investment banking related compensation from the subject company (AGN) within the next 3 months.

---

**Important Regional Disclosures**

The analyst(s) involved in the preparation of this report have not visited the material operations of the subject company (AGN) within the past 12 months.

Restrictions on certain Canadian securities are indicated by the following abbreviations: NVS--Non-Voting shares; RVS--Restricted Voting Shares; SVS--Subordinate Voting Shares.

Individuals receiving this report from a Canadian investment dealer that is not affiliated with CSFB should be advised that this report may not contain regulatory disclosures the non-affiliated Canadian investment dealer would be required to make if this were its own report.

For Credit Suisse First Boston Canada Inc.'s policies and procedures regarding the dissemination of equity research, please visit [http://www.csfb.com/legal\\_terms/canada\\_research\\_policy.shtml](http://www.csfb.com/legal_terms/canada_research_policy.shtml).

As of the date of this report, CSFB acts as a market maker or liquidity provider in the equities securities that are the subject of this report.

---

For disclosure information on other companies mentioned in this report, please visit the website at [www.csfb.com/researchdisclosures](http://www.csfb.com/researchdisclosures) or call +1 (877) 291-2683.

Disclaimers continue on next page.



## Disclaimers

Credit Suisse First Boston is the trade name for the investment banking business of Credit Suisse, a Swiss bank, and references in this report to Credit Suisse First Boston or CSFB herein include all of the subsidiaries and affiliates of Credit Suisse operating under the Credit Suisse First Boston division of Credit Suisse Group ("CSG"). For more information on our structure, please follow the below link: [http://www.creditsuisse.com/en/who\\_we\\_are/ourstructure.html](http://www.creditsuisse.com/en/who_we_are/ourstructure.html).

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Credit Suisse or its subsidiaries or its affiliates ("CS") to any registration or licensing requirement within such jurisdiction. All material presented in this report, unless specifically indicated otherwise, is under copyright to CS. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of CS. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of CSG or its affiliates.

The information, tools and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. CS may not have taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. CS will not treat recipients as its customers by virtue of their receiving the report. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal recommendation to you. CS does not offer advice on the tax consequences of investment and you are advised to contact an independent tax adviser. Please note in particular that the bases and levels of taxation may change.

CS believes the information and opinions in the Disclosure Appendix of this report are accurate and complete. Information and opinions presented in the other sections of the report were obtained or derived from sources CS believes are reliable, but CS makes no representations as to their accuracy or completeness. Additional information is available upon request. CS accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that liability arises under specific statutes or regulations applicable to CS. This report is not to be relied upon in substitution for the exercise of independent judgment. CS may have issued, and may in the future issue, a trading call regarding this security. Trading calls are short term trading opportunities based on market events and catalysts, while stock ratings reflect investment recommendations based on expected total return over a 12-month period relative to the relevant coverage universe. Because trading calls and stock ratings reflect different assumptions and analytical methods, trading calls may differ directionally from the stock rating. In addition, CS may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and CS is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report. CS is involved in many businesses that relate to companies mentioned in this report. These businesses include specialized trading, risk arbitrage, market making, and other proprietary trading.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgement at its original date of publication by CS and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments. Investors in securities such as ADR's, the values of which are influenced by currency volatility, effectively assume this risk.

Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility, and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct their own investigation and analysis of the product and consult with their own professional advisers as to the risks involved in making such a purchase.

Some investments discussed in this report have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when that investment is realised. Those losses may equal your original investment. Indeed, in the case of some investments the potential losses may exceed the amount of initial investment, in such circumstances you may be required to pay more money to support those losses. Income yields from investments may fluctuate and, in consequence, initial capital paid to make the investment may be used as part of that income yield. Some investments may not be readily realisable and it may be difficult to sell or realise those investments, similarly it may prove difficult for you to obtain reliable information about the value, or risks, to which such an investment is exposed. This report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of CSG, CS has not reviewed the linked site and takes no responsibility for the content contained therein. Such address or hyperlink (including addresses or hyperlinks to CSG's own website material) is provided solely for your convenience and information and the content of the linked site does not in any way form part of this document. Accessing such website or following such link through this report or CSG's website shall be at your own risk.

This report is issued and distributed in Europe (except Switzerland) by Credit Suisse First Boston (Europe) Limited, One Cabot Square, London E14 4QJ, England, which is regulated in the United Kingdom by The Financial Services Authority ("FSA"). This report is being distributed in the United States by Credit Suisse First Boston LLC; in Switzerland by Credit Suisse; in Canada by Credit Suisse First Boston Canada Inc.; in Brazil by Banco de Investimentos Credit Suisse First Boston S.A.; in Japan by Credit Suisse First Boston Securities (Japan) Limited; elsewhere in Asia/Pacific by whichever of the following is the appropriately authorised entity in the relevant jurisdiction: Credit Suisse First Boston (Hong Kong) Limited, Credit Suisse First Boston Australia Equities Limited, Credit Suisse First Boston (Thailand) Limited, CSFB Research (Malaysia) Sdn Bhd, Credit Suisse Singapore Branch and elsewhere in the world by the relevant authorised affiliate of the above. Research on Taiwanese securities produced by Credit Suisse Taipei Branch has been prepared by a registered Senior Business Person.

In jurisdictions where CS is not already registered or licensed to trade in securities, transactions will only be effected in accordance with applicable securities legislation, which will vary from jurisdiction to jurisdiction and may require that the trade be made in accordance with applicable exemptions from registration or licensing requirements. Non-U.S. customers wishing to effect a transaction should contact a CS entity in their local jurisdiction unless governing law permits otherwise. U.S. customers wishing to effect a transaction should do so only by contacting a representative at Credit Suisse First Boston LLC in the U.S.

Please note that this report was originally prepared and issued by CS for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of CS should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. This research may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA or in respect of which the protections of the FSA for private customers and/or the UK compensation scheme may not be available, and further details as to where this may be the case are available upon request in respect of this report.

Copyright 2005 CREDIT SUISSE and/or its affiliates. All rights reserved.